Effects of sevoflurane on biomechanical markers of hepatic and renal dysfunction after coronary artery surgery.
OBJECTIVE
The purpose of this study was to compare the effects of a total intravenous and a volatile anesthetic regimen on biochemical markers of hepatic and renal dysfunction after coronary artery surgery.


METHODS
Prospective, double-blind, randomized clinical study.


METHODS
University hospital, single institutional.


METHODS
Three hundred twenty patients undergoing elective coronary artery surgery were divided into 2 different anesthetic protocols: propofol group (n = 160) and sevoflurane group (n = 160).


METHODS
Hemodynamic data were registered before the start of surgery, before the start of CPB, 15 minutes after the end of CPB, at arrival in the intensive care unit, and 6 and 12 hours after arrival in the intensive care unit. Serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), serum lactate dehydrogenase (LDH), and serum creatinine concentrations were measured before surgery, at arrival in the intensive care unit, and after 6, 12, 24, and 48 hours.


RESULTS
Postoperative levels of serum SGOT, SGPT, and LDH increased transiently in both anesthetic groups, but the increase was significantly lower in the sevoflurane group compared with the propofol group. Creatinine levels remained largely unchanged in both groups.


CONCLUSIONS
Postoperative biochemical markers of hepatic dysfunction were lower with a sevoflurane-based anesthetic regimen in patients undergoing coronary artery surgery with cardiopulmonary bypass.
Lorsomradee
Suraphong
S
Department of Anesthesiology, University Hospital, Antwerp, Edegem, Belgium.
Cromheecke
Stefanie
S
Lorsomradee
Sratwadee
S
De Hert
Stefan G
SG
D000280:Administration, Inhalation; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000768:Anesthesia, General / Q000379:methods*; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D002315:Cardiopulmonary Bypass / Q000379:methods; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003327:Coronary Disease / Q000097:blood / Q000601:surgery*; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000209:etiology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008107:Liver Diseases / Q000097:blood* / Q000209:etiology; D008297:Male; D008738:Methyl Ethers / Q000008:administration & dosage*; D011379:Prognosis; D011446:Prospective Studies; D000077149:Sevoflurane
D018685:Anesthetics, Inhalation; D015415:Biomarkers; D008738:Methyl Ethers; D000077149:Sevoflurane; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase